Nuvigil Label Likely To Include Safety Information From Sparlon Trials
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Final approved labeling for Cephalon’s Nuvigil (armodafinil) will likely include results of an FDA safety review for the firm’s other pending product, attention deficit hyperactivity disorder treatment Sparlon (modafinil).